

Auswahl an Publikationen von Prof. Schmidt-Wolf zum Lymphom:

1. Schmidt-Wolf IGH, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse / human lymphoma model to evaluate cytokine-induced killer cells with potent anti-tumor cell activity. *J Exp Med* 174(1):139-149 (1991; cited in *Science* 259:1463 (1993))
2. Schlegel PG, Schmidt-Wolf G, Schmidt-Wolf IGH, Kwak LW, Chao NJ. Lymphokine-activated killer cell activity against autologous lymphoma cells following bone marrow transplantation. *Cancer Research, Therapy and Control* Vol.3:145 -152 (1993)
3. Schmidt-Wolf IGH, Neubauer A, Finke S, Csipai M, Wittig B, Huhn D. Interleukin-7 gene therapy for patients with metastatic colon cancer, renal cell cancer, malignant melanoma or lymphoma. *Human Gene Ther* 5(9), 1161-1168 and 1197 (1994)
4. Schmidt-Wolf IGH, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D. Phase I clinical study applying autologous immunologic effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. *Brit J Cancer* 81(6):1009-1016 (1999)
5. Lefterova P, Märten A, Buttgereit P, Schakowski F, Micka B, Scheffold C, Schmidt-Wolf IGH. Induction of apoptosis in B lymphoma cells by activation with CD40L. *Acta Haematologica* 103(3):168-171 (2000)
6. Lefterova P, Märten A, Buttgereit P, Weineck S, Huhn D, Scheffold C, Schmidt-Wolf IGH. Targeting of NK-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody dependent cellular cytotoxicity. *J Immunother* 23(3):304-310 (2000)
7. Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt-Wolf I. Mechanism of cytotoxicity induced by the chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20 expressing lymphoma cell lines. *Cellular Immunology* 204: 55-63 (2000)
8. Schlegel U, Schmidt-Wolf IGH, Deckert M. Primary CNS lymphoma: Clinical presentation, pathological classification, molecular pathogenesis and treatment. *J Neurol Sciences* 181(1-2):1-12 (2000)
9. Buttgereit P, Weineck S, Röpke G, Märten A, Brand K, Heinicke T, Caselmann WH, Huhn D, Schmidt-Wolf IGH. Efficient gene transfer into lymphoma cells using adenoviral vectors combined with lipofection. *Cancer Gene Ther* 7(8):1145-1155 (2000)
10. Pels H, Glasmacher A, Schmidt-Wolf IGH, Schlegel U. Therapie primärer cerebraler Lymphome. *Aktuelle Neurologie* 28:189-194 (2001)
11. Schlegel U, Pels H, Glasmacher A, Kleinschmidt R, Schmidt-Wolf I, Helmstaedter C, Fließbach K, Deckert-Schlüter M, Van Roost D, Fimmers R, Bode U, Klockgether T. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. *J Neurol Neurosurg Psychiatry* 71(1):118-122 (2001)
12. Buttgereit P, Schakowski F, Märten A, Brand K, Renoth S, Ziske C, Schöttker B, Ebert O, Schroers R, Schmidt-Wolf IGH. Effects of adenoviral wild-type p53 gene transfer in p53-mutated lymphoma cells. *Cancer Gene Therapy* 8(6):430-439 (2001)
13. Korfel A, Finke J, Schmidt-Wolf I, Thiel E. 5. Report on workshop: Primary CNS lymphoma. *Ann Hematol.* 80 Suppl 3:B20-23 (2001)
14. Buttgereit P, Schmidt-Wolf IGH. State-of-the-art review. Gene therapy of lymphoma. *J Hematother & Stem Cell Res* 11(3): 457-467 (2002)
15. Schmidt-Wolf IGH, Rockstroh JK, Schlegel U, Pels H, Weiss R, Huhn D. New aspects in the treatment of AIDS-related lymphoma. *Eur J Med Research* 7(7):295-303 (2002)
16. Klaus Fliessbach, Horst Urbach, Christoph Helmstaedter, Hendrik Pels, Axel Glasmacher, Jürgen A. Kraus, Thomas Klockgether, Ingo Schmidt-Wolf, Uwe Schlegel. Cognitive

- Performance and MRI Findings after High Dose Systemic and Intraventricular Chemotherapy for Primary CNS Lymphoma. *Archives of Neurology* 60:563-568 (2003)
17. Schmidt-Wolf IGH, Rockstroh JK, Schlegel U, Pels H, Mey U, Strehl J, Weiss R, Huhn D. Treatment options of AIDS-related lymphoma. *Expert Opinion on Pharmacotherapy* 4(8):1331-1343 (2003).
 18. Strehl J, Mey U, Glasmacher A, Djulbegovic B, Mayr C, Gorschlüter M, Ziske C, Schmidt-Wolf IG. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. *Haematologica*. 2003 Nov;88(11):1304-15
 19. Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, Schlegel U. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. *J Clin Oncol*. 2003 Dec 15;21(24):4489-95. Epub 2003 Nov 3
 20. Linnebank M, Schmidt S, Kölsch H, Linnebank A, Heun R, Schmidt-Wolf IGH, Glasmacher A, Fließbach K, Klockgether T, Schlegel U, Pels H. The methionine synthase polymorphism D919G alters susceptibility to primary central nervous system lymphoma. *Brit J Cancer* 90:1969-1971 (2004)
 21. Schulz H, Pels H, Schmidt-Wolf IGH, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed CNS lymphomas with the anti-CD20 antibody rituximab. *Haematologica* 89(6): 753-754 (2004)
 22. Leo E, Scheuer L, Schmidt-Wolf IGH, Kerowgan M, Schmitt C, Leo A, Baumbach T, Kraemer A, Benner, Parwaresch R, Ho AD. Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma. *European J Hematol* 73:251-257 (2004)
 23. Ebert O, Wilbert D, Buttgereit P, Ziske C, Flieger D, Sauerbruch T, Schmidt-Wolf IGH. Effects of recombinant IL-2 and IL-12 in human B lymphoma cells on co-cultured lymphocytes. <http://www.gvt-journal.com/content/2/1/15>
 24. Pels H, Montesinos-Rongen M, Schaller C, Schlegel U, Schmidt-Wolf IG, Wiestler OD, Deckert M. VH gene analysis of primary CNS lymphomas. *J Neurol Sci*. 2005 Feb 15;228(2):143-7. Epub 2004 Dec 19
 25. Fließbach K, Helmstaedter C, Urbach H, Althaus A, Pels H, Linnebank M, Juergens A, Glasmacher A, Schmidt-Wolf IGH, Klockgether T, Schlegel U. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. *Neurology* 64(7):1184-1188 (2005)
 26. H. Palmedo, H. Bender, H. Urbach, U. Schlegel, I.G.H. Schmidt-Wolf, A. Matthies, A. Joe, J. Bucerius, H.-J. Biersack, H. Pels. Primary diagnosis and therapeutic monitoring of primary central nervous system lymphoma with FDG-PET in immunocompetent patients: correlation with MRI and clinical follow-up. *Eur J Nucl Med Mol Imaging*, Oct 12 (2005) IPF 3,9
 27. Rudolf Weiss, Paris Mitrou, Keikawus Arastéh, Dirk Schuermann, Hannelore Seibt, Birgit Ross, Thomas Kubin, Markus Hentrich, Ulrich Duehrsen, Hans Pees, Bernhard Fleischer, Christoph Heese, Ingo Schmidt-Wolf, Ioannis Anagnostopoulos, Dieter Huhn. AIDS-related lymphoma (ARL): Simultaneous treatment with CHOP chemotherapy and with highly active antiretroviral therapy (HAART) is save and improves survival. Results of the German multicenter trial for the treatment of AIDS-related lymphomas. *Cancer* 106(7):1560-1568 (2006)
 28. Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M, Bopp C, Gorschlüter M, Wilhelm M, Birkmann J, Kaiser U, Neubauer A, Florschütz A, Rabe C, Hahn C, Glasmacher AG, Schmidt-Wolf IG. Dexamethasone, high-dose cytarabine, and cisplatin in

- combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. *Cancer Invest.* 2006 Oct;24(6):593-600
29. Mey U, Olivieri A, Orlopp K, Rabe C, Strehl J, Gorschlüter M, Hensel M, Flieger D, Glasmacher A, Schmidt-Wolf IGH. DHAP in combination with rituximab versus DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. *Leukemia & Lymphoma* 47(12):2558-2566 (2006)
 30. Mey U, Maier A, Schmidt-Wolf IGH, Ziske C, Forstbauer H, Banat GA, Reber M, Strehl J, Gorschlüter M. Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. *Supportive Care in Cancer*, online, 2007 Jan 19
 31. Courts C, Montesinos-Rongen M, Martin-Subero JI, Brunn A, Bechtel D, Zühlke-Jenisch R, Pels H, Jürgens A, Schlegel U, Schmidt-Wolf IGH, Schaller C, Reifenberger G, Sabel M, Warnecke-Eberz U, Wiestler OD, Küppers R, Siebert R, Deckert M. Transcriptional profiling of the NF- κ B pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression and unfavorable prognosis. *J Neuropathol Exp Neurol* 66(3):230-237 (2007)
 32. Mey UJM, Jha V, Strehl JW, Gorschlüter M, Rabe C, Hoebert E, Popp H, Schmidt-Wolf IGH. High dose chemotherapy with autologous stem cell transplantation in diffuse large B-cell lymphoma. *GMS* 5:2007
 33. Linnebank M, Moskau S, Jurgens A, Simon M, Semmler A, Orlopp K, Glasmacher A, Bargart C, Vogt-Schaden M, Urbach H, Schmidt-Wolf IG, Pels H, Schlegel U. Association of genetic variants of methionine metabolism with MTX-induced CNS white matter changes in patients with primary central nervous system lymphoma. *Neuro Oncol.* 2008 Sep 22.
 34. Shimomura A, v. Lilienfeld-Toal M, Balta Z, Schroers E, Schmidt-Wolf IGH, Büttner R, von Rücker A, Gütgemann I. Lack of Surface and Cytoplasmic Immunoglobulin Light Chains in a HIV-related Burkitt Lymphoma. *Ann Hematol*, in Druck
 35. Pels H, Juergens A, Glasmacher A, Schulz H, Engert A, Linnebank M, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Lamprecht M, Hau P, Deckert M, Fimmers R, Bangard C, Schmidt-Wolf IGH, Schlegel U. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. *J Neurooncol.* 2009 Feb;91(3):299-305.
 36. Schmidt M, Sievers E, Endo T, Lu D, Carson D, Schmidt-Wolf IGH. Targeting Wnt pathway in lymphoma and myeloma cells. *Brit J Haematol.* 2009 Mar;144(5):796-8.
 37. Juergens A, Pels H, Rogowski S, Fliessbach K, Glasmacher A, Engert A, Reiser M, Diehl V, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Kroschinsky F, Bode U, Herrlinger U, Linnebank M, Deckert M, Fimmers R, Schmidt-Wolf IGH, Schlegel U. Long-term survival with favorable cognitive outcome after chemotherapy in Primary Central Nervous System Lymphoma. *Ann Neurol* 66:.....(2009)
 38. Hendrik Pels*, Annika Juergens*, Isabell Schirgens, Axel Glasmacher, Holger Schulz, Andreas Engert, Gabriele Schackert, Heinz Reichmann, Frank Kroschinsky, Marlies Vogt-Schaden, Gerlinde Egerer, Udo Bode, Martina Deckert, Rolf Fimmers, Horst Urbach, Ingo G.H. Schmidt-Wolf, Uwe Schlegel. Early complete response during chemotherapy predicts favourable outcome in patients with primary CNS lymphoma. *Neurooncology*, 2010 Jul;12(7):720-4, Epub 2010 Feb 16
 39. ¹Anjali Advani, MD; ²Hemant Patel, PhD; ²Joe Boni, PhD; ³Bertrand Coiffier, MD; ⁴Myron S. Czuczman, MD; ⁵Martin Dreyling, MD; ⁶James Foran, MD; ⁷E. Gine, MD; ⁸Christian Gisselbrecht, MD; ⁹Nicolas Ketterer, MD; ¹⁰Sunita Nasta, MD; ¹¹A. Rohatiner, MD; ¹²Ingo G.H. Schmidt-Wolf, MD; ¹³Martin Schuler, MD; ¹⁴Jorge Sierra, MD; ¹⁵Mitchell Smith, MD; ¹⁶Gregor Verhoef, MD; ¹⁷J. Winter, MD; ²Mark Shapiro, MD, PhD;

- ¹⁸Luis Fayad, MD. A Phase 1 Study of Inotuzumab Ozogamicin (CMC-544) as Treatment for B-Cell Non-Hodgkin's Lymphoma: JCO Apr 20;28(12):2085-93 (2010)
40. Ingo G.H. Schmidt-Wolf (1), Hendrik Pels (2), Annika Jürgens (2), Katrin Patrij (1), Luise Wätzel (3), Ulrich Herrlinger (1), Holger Schulz (3), Andreas Engert (3), Michael Linnebank (1), Gabriele Schackert (4), Heinz Reichmann (4), Frank Kroschinsky (4), Marlies Vogt-Schaden (5), Gertlinde Egerer (5), Carlo Schaller (3), Monika Lamprecht (6), Peter Hau (7), Martina Deckert (3), Rolf Fimmers (1), Christoph Bangard (3), Marcel Reiser (3). Relapse of central nervous system lymphoma (CNSL) AFTER SYSTEMIC LYMPHOMA (SCNSL): Clinical features and outcome AS COMPARED TO PRIMARY CNS LYMPHOMA (Pcnsl) PATIENTS. GMS, May 2; 2011
41. Patrij K, Reiser M, Wätzel L, Pels H, Kowoll A, Herrlinger U, Engert A, Linnebank M, Schackert G, Vogt-Schaden M, Egerer G, Lamprecht M, Batchelor TT, Schlegel U, Schmidt-Wolf IG; International Primary CNS Lymphoma Collaborative Group (IPCG). Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis. Ger Med Sci. 2011;9:Doc11. doi: 10.3205/000134. Epub 2011 May 2.
42. Stuplich M, Mayer K, Kim Y, Thanendrarajan S, Simon M, Schäfer N, Glas M, Schmidt-Wolf IG, Herrlinger U. Richter syndrome and brain involvement: low-grade lymphoma relapsing as cerebral high-grade lymphoma. Acta Haematol. 2012;127(2):93-5. doi: 10.1159/000334068. Epub 2011 Dec 10.10.
43. Linnebank M, Moskau S, Kowoll A, Semmler A, Bangard C, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Schmidt-Wolf IG, Pels H, Schlegel U. Association of transcobalamin c. 776C>G with overall survival in patients with primary central nervous system lymphoma. Br J Cancer. 2012 Nov 20;107(11):1840-3. doi: 10.1038/bjc.2012.476. 2012. (IF5,0)
44. F. McClanahan¹, T. Hielscher², M. Rieger¹, M. Hensel³, M. Bentz⁴, I. Schmidt-Wolf⁵, A. Käbisch⁶, H. Salwender⁷, H. Dürk⁸, H. Staiger⁹, T. Mandel¹⁰, K. Neben¹, J. Hillengass¹, A.D. Ho¹, M. Witzens-Harig¹. Final results of a prospective, multicentre, randomized trial comparing 1, 3 or 6 infusions of Rituximab combined with 6 cycles of CHOP chemotherapy in untreated patients with advanced follicular lymphoma (HD2000 trial). Am J Hematol 2012 Oct;87(10):E68-71. IF: 3,6
45. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balsler C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W et al. (Study group indolent Lymphomas (StiL)). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 Apr 6;381(9873):1203-10. IF:38,3
46. Khristi J, Gütgemann I, Schmidt-Wolf I. Composite lymphoma: case reports and review of the literature. Annals Hematol, 2013 Apr 5. IF: 2,6
47. Khristi J, Mey U, Kirfel J, Schmidt-Wolf IG, Gütgemann I. Sequential Hodgkin's and non-Hodgkin's lymphoma in non-immunocompromised patients. Ann Hematol. 2013 Nov;92(11):1565-7. doi: 10.1007/s00277-013-1742-0.
48. Gast SM et al. Wnt pathway in lymphoma and myeloma. Review. Drugs of the Future. In Druck. IF 0,6